While this has good intentions, I’m worried about the safety since not just anyone has the expertise, quality control and knowledge on producing it safely.
There will be companies that values mass reach/volume over efficacy and guess who will be on the receiving end of such a batch of vaccines, it’ll be the developing countries again.
Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
